Poolbeg Pharma PLC
POLB
Company Profile
Business description
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to development of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.
Contact
42 New Road
Queen Mary BioEnterprises Innovation Centre
LondonE1 2AX
GBRT: +44 2071831499
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
10
Stocks News & Analysis
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,122.00 | 0.50 | 0.01% |
| CAC 40 | 7,895.94 | 15.07 | 0.19% |
| DAX 40 | 23,880.72 | 135.66 | 0.57% |
| Dow JONES (US) | 46,397.89 | 81.82 | 0.18% |
| FTSE 100 | 9,350.43 | 50.59 | 0.54% |
| HKSE | 26,855.56 | 232.68 | 0.87% |
| NASDAQ | 22,660.01 | 68.86 | 0.30% |
| Nikkei 225 | 44,544.19 | 388.44 | -0.86% |
| NZX 50 Index | 13,433.99 | 141.63 | 1.07% |
| S&P 500 | 6,688.46 | 27.25 | 0.41% |
| S&P/ASX 200 | 8,831.20 | 2.20 | -0.02% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |